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Certain caspase-8 null cell lines demonstrate resistance to Fas-induced apoptosis, indicating that the Fas/FasL apoptotic pathway may
be caspase-8-dependent. Some reports, however, have shown that Fas induces cell death independent of caspase-8. Here we provide
evidence for an alternative, caspase-8-independent, Fas death domain-mediated apoptotic pathway. Murine 12B1-D1 cells express
procaspase-3, -8, and -9, which were activated upon the dimerization of Fas death domain. Bid was cleaved and mitochondrial trans-
membrane potential was disrupted in this apoptotic process. All apoptotic events were completely blocked by the broad-spectrum
caspase inhibitor Z-VAD-FMK, but not by other peptide caspase inhibitors. Cyclosporin A (CsA), which inhibits mitochondrial tran-
sition pore permeability, blocked neither pore permeability disruption nor caspase activation. However, CsA plus caspase-8 inhibitor
blocked all apoptotic events of 12B1-D1 induced by Fas death domain dimerization. Our data therefore suggest that there is a novel,
caspase-8-independent, Z-VAD-FMK-inhibitable, apoptotic pathway in 12B1-D1 cells that targets mitochondria directly.
INTRODUCTION
Fas (CD95, APO-1), a member of the tumor necro-
sis factor receptor family, is a widely expressed cell death
receptor that plays a critical role in the regulation of the
immune system and tissue homeostasis [1, 2]. Fas or Fas
ligand (FasL) mutations in humans and mice cause syn-
dromesofmassivelymphoproliferationandautoantibody
production [1]. Fas-induced apoptosis is a major mecha-
nism in cytotoxic T-lymphocyte-mediated cytolysis [3].
Fas death domain (FasDD) is an approximately 80
amino acid intracellular motif of Fas that is critical for
signaling apoptosis [4]. The activation of Fas by FasL or
by agonistic antibody leads to the trimerization of FasDD,
which consequently recruits FADD (Fas-associated pro-
teinwithdeathdomain)orMORT1,andcaspase-8,form-
ing the so-called death-inducing signal complex (DISC)
[5]. Formation of DISC leads to activation of caspase-8,
an initiator of downstream apoptotic processes that in-
clude the activation of caspase-3, -6, and -7 and loss of
mitochondrial transmembrane potential (MTP) [6].
Caspase-8 plays a key role in Fas-induced apopto-
sis [7, 8, 9]. Certain transgenic mice or cell lines deﬁ-
cient in caspase-8 have been shown to be resistant to
Fas-induced apoptosis [10, 11], suggesting that caspase-
8 may be essential in Fas-mediated apoptosis. Reports
suggest that there may be two alternative Fas signaling
pathways [12]. In the Fas “type I” cells, relatively large
amountsofcaspase-8arerecruitedtoDISCuponreceptor
cross-linking,resultingintheactivationofcaspase-8.This
initiates a rapid apoptotic signal by directly activating
downstream eﬀector caspases through proteolytic cleav-
age, as well as by triggering mitochondrial damage lead-
ing to a proteolytic cascade. In Fas “type II” cells, the rel-
atively slowly activated caspase-8 mediates downstream
apoptotic events mainly by inducing mitochondrial dam-
age[12].Recently,YangetalshowedthatFascouldengage
an apoptotic pathway independent of FADD and caspase-
8[ 13]. Fas activation induced Daxx to interact with apop-
tosis signal-regulating kinase 1 (ASK1). ASK1’s activated
kinase activity resulted in caspase-independent activation
of c-Jun N-terminal kinase (JNK), leading to cell death
[14, 15]. In addition, several reports have now shown
that Fas signaling can trigger an alternative, caspase-8-
independent necrotic cell death pathway [16, 17, 18].
Taken together, these results indicate that Fas-mediated
cell death is much more complicated than originally
thought.
In this study, using a BCR-ABL+ leukemia cell line
12B1-D1, we have demonstrated that a broad-spectrum
peptide caspase inhibitor, Z-VAD-FMK (pan-caspase in-
hibitor), completely blocked FasDD-mediated cell death.
PeptidecaspaseinhibitorZ-IETD-FMK(casp-8inhibitor)
or Z-DEVD-FMK (casp-3 inhibitor) blocked neither the
disruption of MTP nor chromosomal DNA fragmenta-
tion after activation of FasDD. However, all apoptotic
events were completely blocked when 12B1-D1 cells were
pretreated with cyclosporin A (CsA) and casp-8 inhibitor42 Hanping Feng et al 2004:1 (2004)
followed by dimerization of FasDD. This suggests that
FasDD triggers a novel caspase-8-independent apoptotic
pathway in the 12B1-D1 leukemia cell line.
MATERIALS AND METHODS
Antibodiesandreagents
Anti-caspase-3 (clone 46) and anti-caspase-7 (clone
10-1-62) antibodies were purchased from BD PharMin-
gen (Franklin Lakes, NJ). Rabbit anti-caspase-8 poly-
clonal antibody was from StressGen Biotechnologies
(Victoria, BC, Canada). Anti-caspase-9 antibody (clone
9CSP02) was from NeoMarkers (Fremont, Calif). Goat
anti-human/mouse BID antibody and anti-caspase-10
antibody (clone Mch 2) were purchased from R&D
Systems (Minneapolis, Minn). Cyclosporin A was from
Sigma (St. Louis, Mo). Peptide caspase inhibitors, ben-
zyloxycarbonyl Val-Ala-Asp-ﬂuoromethylketone (abbre-
viated Z-VAD-FMK) pan-caspase inhibitor, Z-WEHD-
FMK caspase-1 inhibitor, Z-VDVAD-FMK caspase-2 in-
hibitor, Z-DEVD-FMK caspase-3 inhibitor, Z-YVAD-
FMK caspase-4 inhibitor, Z-VEID-FMK caspase-6 in-
hibitor, Z-IETD-FMK caspase-8 inhibitor, Z-LEHD-FMK
caspase-9 inhibitor, Z-AEVD-FMK caspase-10 inhibitor,
Z-LEED-FMK caspase-13 inhibitor, and Z-FA-FMK con-
trol faux inhibitor, were all from R&D Systems. 3,3 -
dihexyloxacarbocyanine iodide (DiOC6[3]) was from
Molecular Probes (Eugene, Ore).
Determinationofcaspaseactivities
Caspase activities from cytosolic extracts were mea-
sured using a ﬂurometric assay according to the manu-
facturer’s instructions (R&D Systems). In brief, 12B1-D1
cells were collected by centrifugation (1000 ×g, 5 min-
utes, 4◦C). Cells were washed with ice-cold PBS and re-
suspended in chilled lysis buﬀer. After 10 minutes on
ice, the supernatant was collected following centrifu-
gation (10000 ×g) and was assayed for protein con-
tent using the bicinchonic acid reagent (Pierce, Rock-
ford, Ill). For caspase activity measurements, cell ex-
tract (50µg) was incubated at 37◦C in the kit’s reaction
buﬀercontainingthesubstratesAsp-Glu-Val-Asp-amino-
4-triﬂuoromethyl courmarin (DEVD-AFC), Ile-Glu-Thr-
Asp-amino-4-triﬂuoromethyl courmarin (IETD-AFC),
or Leu-Glu-His-Asp-amino-4-triﬂuoromethyl courmarin
(LEHD-AFC). After 1.5 to 2 hours incubation at 37◦C,
the ﬂuorescence intensity (excitation at 390nm, emission
at 510nm) was measured using a microplate ﬂuorometer
(Labsystems, Franklin, Mass).
Flowcytometryanalysis
Annexin V-FITC/PI staining of apoptotic cells was
previously described [19]. To evaluate MTP disruption,
the cationic lipophilic ﬂuorochrome DiOC6[3] was used
[20]. Cells were incubated with 40nM DiOC6[3] for 15
minutes at 37◦C. Alternatively, MTP was measured using
a DePsipher kit (R&D Systems) following the manufac-
turer’s instructions. Stained cells were analyzed by ﬂow
cytometry.
DNAfragmentationassay
Nucleosomal DNA fragmentation was analyzed as de-
scribed previously [19].
Immunoblotting
The cleavage of Bid and several caspases were de-
tected by western blotting as described previously [19].
Brieﬂy, lysates containing 25µg of protein were separated
by electrophoresis through 15% SDS-PAGE gels and pro-
teins were transferred to nitrocellulose membranes. Equal
loadingwasconﬁrmedbyPonceauSstainingofthemem-
branes. Caspase-3, -7, -9, -10, and Bid were detected us-
ingrelevantprimaryantibodiesandalkalinephosphatase-
conjugated secondary antibodies (Chemicon, Temecula,
Calif) followed by color deposition of the substrates
NBT/BCIP (Roche Molecular Biochemicals, Indianapolis,
Ind).
RESULTS
Caspaseactivationandapoptosisinduction
of12B1-D1cellsafterdimerization
ofengineeredFasDD
We have previously reported that the BCR-ABL+ cell
line 12B1 does not express Fas protein on its surface and
consequently fails to undergo apoptosis in response to
anti-Fas antibody [19]. Therefore, we stably transfected
12B1 cells with plasmid DNA encoding a fusion protein
that consists of the extracellular domain of the human
low aﬃnity nerve growth factor receptor (NGFR), two
copies of mutant FK506 binding proteins (FKBP), and
the FasDD (see [19]a n dFigure 1a). One clone, 12B1-
D1, was further studied. Treatment of 12B1-D1 cells with
the semisynthetic FK506 derivative AP20187 resulted in
dimerization of FasDD and rapid induction of apoptosis
[19]. More than 80% of the cells became annexin V-FITC
positive within 4 to 6 hours of 40 nM AP20187 treat-
ment (Figure 1b). In addition, the chromosomal DNA
was cleaved into 200-bp fragments, a typical feature of
apoptosis, after 6 hours AP20187 treatment (Figure 1c).
The opening of mitochondrial pores is an early event
of many types of apoptosis, leading to the depolariza-
tion of MTP. We used the potential-sensitive mitochon-
drial probe DiOC6[3] for the cytoﬂuorometric determi-
nation of MTP during FasDD-induced apoptosis. Treat-
ment of 12B1-D1 cells with AP20187 resulted in a marked
decrease in the retention of DiOC6[3] within 3 hours
and more than 70% of cells lost MTP within 5 hours
(Figure 1d).
To analyze caspase activities after AP20187 treat-
ment, we used ﬂuorochrome-conjugated caspase speciﬁc
peptide substrates, LEHD-AFC, IETD-AFC, or DEVD-
AFC for caspase-9, -8, or -3, respectively. All three
caspases were activated within 30 minutes of AP201872004:1 (2004) A Novel Fas Death Domain Apoptotic Pathway 43
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Figure 1. “Death construct” and apoptosis induction of 12B1-D1 cells by AP20187 treatment. (a) Transmembrane fusion protein
consisting of a low-aﬃnity nerve growth factor receptor (NGFR) accessible on the cell surface, two mutant FK506-binding pro-
tein (FKBP) domains, and a Fas death domain (FasDD) intracellularly. AP20187 serves to dimerize FKBP domains, thus dimerizing
FasDD. (b) 12B1-D1 cells were treated with 40nM AP20187 for the indicated time, washed, and then stained with Annexin V and
PI. (c) DNA fragmentation analysis. Lane 1, 100-bp ladder; lane 2, DNA extracted from 12B1-D1 cells; lane 3, DNA extracted from
12B1-D1 cells that have been treated with AP20187 for 6 hours. (d) 12B1-D1 cells were treated with AP20187 for the indicated time,
washed, and then stained with mitochondrial probe DiOC6[3]. The ﬂuorescence intensity was measured by ﬂow cytometry.
treatment, and reached maximum activity after 2 hours
as judged by increasing ﬂuorescence intensity (Figure 2),
following caspase cleavage of substrates and release
of the ﬂuorochrome AFC. We also analyzed caspase
activation during AP20187-induced apoptosis by western
blot (Figure 3). Procaspase-3, a main eﬀector caspase,
began to be cleaved within 30 minutes of AP20187
treatment (Figure 3a). Longer exposure of 12B1-D1 cells
to AP20187 increased the intensity of a 17-kd fragment.
Eﬀector caspases procaspase-7 (35-kd protein, Figure 3b)
and procaspase-9 (46–48-kd protein to 37-kd frag-
ment, Figure 3c) were also cleaved within 30 minutes of
AP20187 treatment. Consistent with another report [10],
we found that although caspase-10 was expressed in
12B1-D1 cells, it was not proteolytically cleaved
(Figure 3b).44 Hanping Feng et al 2004:1 (2004)
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Figure 2. 12B1-D1 caspase activities after AP20187 treatment.
12B1-D1 cells were treated with 40 nM AP20187 for the indi-
cated time, then washed and lysed. Cell extracts were incubated
at 37◦C for 1.5 to 2 hours in a reaction buﬀer containing the
substrates DEVD-AFC, IETD-AFC, or LEHD-AFC for caspase-
3, -8, and -9, respectively. The activities of the listed caspases
are shown as ﬂuorescence units (FU) and measured using a mi-
croplate ﬂuorometer.
Theeffectofoligopeptidecaspaseinhibitors
oncaspaseactivationand
FasDD-mediatedapoptosis
Irreversible oligopeptide caspase inhibitors have been
used to study the role of diﬀerent caspases in apoptosis.
Z-IETD-FMK and Z-DEVD-FMK block caspase-8- and
caspase-3-like proteases, respectively, whereas Z-VAD-
FMK is a broad-range pan-caspase inhibitor [21, 22]. To
test whether these potent and selective inhibitors could
block FasDD-induced cell death in 12B1-D1 cells, cells
were pretreated with 100µM of pan-caspase inhibitor,
casp-3 inhibitor, or casp-8 inhibitor followed by expo-
sure to AP20187. As in other studies [23], the pan-
caspase inhibitor completely prevented cells from under-
going apoptosis after activation of FasDD, as determined
by the block of the phosphatidyl serine (PS) externaliza-
tion (Figure 4a) and chromosomal DNA fragmentation
(Figure 4b).Moreover,cellscompletelyexcludedtheDNA
dyepropidiumiodide(PI)evenafter13hoursofAP20187
treatment (data not shown), suggesting that this pan-
caspase inhibitor could completely block both FasDD-
induced apoptosis and necrosis. Surprisingly, we found
that the casp-8 or casp-3 inhibitors could not prevent
all major apoptotic events induced by dimerization of
FasDD, such as PS externalization (Figure 4a) and DNA
fragmentation (Figure 4b). As expected, the cells even-
tually developed secondary necrosis (inability to exclude
PI, data not shown). Apoptotic cell death occurred de-
spite clear activity of the caspase inhibitors, as 12B1-D1
cells treated with the inhibitors showed no caspase-3- or
0 30min 2h 4h
Procaspase-3 (32kd)
Casp-3 fragment p17
(a)
0 30min 2h
Procaspase-10
Procaspase-7 (35kd)
(b)
01 0 m i n 3 0 m i n 2 h4 h
Procaspase-9 (46–48kd)
Fragments (35 & 37kd)
(c)
Figure 3. Procaspase cleavage after AP20187 treatment of 12B1-
D1cells.12B1-D1cellsweretreatedwith40nMAP20187forthe
indicated time, then washed and lysed. Speciﬁc caspase cleav-
agewasdeterminedbywesternblottingusinganti-caspase-3(a),
anti-caspase-7 and anti-caspase-10 (b) and anti-caspase-9 (c)
antibodies.
8-dependent-DEVD-AFC or -IETD-AFC cleaving activ-
ity in lysates (Figure 5). In addition, increasing concen-
trations of casp-8 inhibitor up to 200µM did not alter
its inability to block apoptosis, whereas pan-caspase in-
hibitor completely prevented apoptosis even at a substan-
tial lower concentration (20µM, data not shown). Other
peptide caspase inhibitors for caspase-1, -2, -4, -6, -10,
and -13 (see Materials and Methods for inhibitor details)
also did not block the externalization of PS (data not
shown), which occurs early during the apoptotic process
[24].
We examined the activation of caspase-3 after
AP20187 treatment in the presence of pan-caspase in-
hibitor or casp-8 inhibitor (Figure 6) using western blot-
ting to detect the altered migration of the activated form
ofcaspase-3.Casp-8inhibitorperhapsslightlydelayedthe
cleavageoftheproformofcaspase-3butdidnotappearto
block it. In contrast, the pan-caspase inhibitor completely
blocked caspase-3 cleavage.2004:1 (2004) A Novel Fas Death Domain Apoptotic Pathway 45
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Figure 4. Apoptosis induction of 12B1-D1 cells in the presence of peptide caspase inhibitors. (a) 12B1-D1 cells were pretreated with
the indicated peptide caspase inhibitors (100µM) for 30 minutes followed by 6 hours of AP20187 exposure, then washed and stained
with Annexin V and PI staining. The inhibitors used were caspase inhibitor control, Z-FA-FMK; pan-caspase inhibitor, Z-VAD-
FMK; caspase-3 inhibitor, Z-DEVD-FMK; caspase-8 inhibitor, Z-IETD-FMK; and caspase-9 inhibitor, Z-LEHD-FMK. The x-axis on
the ﬂow diagrams is the ﬂuorescence height of Annexin V-FITC, in units from 100 to 104; the y-axis is the ﬂuorescence height of
propidium iodide (PI) in the same scale. (b) DNA fragmentation analysis: M, 100-bp ladder; lane 1, DNA extracted from 12B1-D1
cells; lane 2, DNA from 12B1-D1 cells pretreated with DMSO, or (lane 3) control caspase inhibitor (inhibitors as listed in (a)); lane 4,
DNA extracted from 12B1-D1 cells that have been treated with AP20187 for 6 hours; lane 5, DNA from cells pretreated with caspase
inhibitorcontrol,or(lane6)withpan-caspaseinhibitor,(lane7)withcasp-8inhibitor,or(lane8)withcasp-3inhibitor,eachfollowed
by 6 hours of AP20187 treatment.46 Hanping Feng et al 2004:1 (2004)
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Figure 5. Caspase activities of 12B1-D1 cells in the presence of caspase inhibitors. 12B1-D1 cells, with or without pretreatment with
the indicated caspase inhibitors (as listed in Figure 4a), were exposed to 40 nM AP20187 for the indicated time, then washed and
lysed. Cell extracts were incubated at 37◦C for 1.5 to 2 hours in a reaction buﬀer containing the substrates IETD-AFC (caspase-8
substrate, left), or DEVD-AFC (caspase-3 substrate, right). The ﬂuorescence intensity (in ﬂuorescence units, FU) was measured using
a microplate ﬂuorometer.
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Figure 6. 12B1-D1 caspase-3 cleavage in the presence of caspase inhibitors. 12B1-D1 cells, with or without pretreatment of indicated
caspase inhibitors (as listed in Figure 4a), were treated with 40nM AP20187 for the indicated time, then washed and lysed. Caspase-3
cleavage was determined by western blotting using anti-caspase-3 antibody. AP refers to the FKBP binding drug AP20187.
It has been reported that there are two types of cells
in terms of Fas-mediated apoptosis [12], type I and type
II cells. In type I cells, a signiﬁcant amount of caspase-
8 is rapidly activated after Fas/FasL ligation, resulting in
a strong signal which can bypass mitochondria and di-
rectly target eﬀector caspases, such as caspase-3. Total
procaspase-8expression(determinedbywesternblotting)
by 12B1-D1 cells is signiﬁcant when compared to some
other mouse tumor cell (data not shown). After dimer-
ization of FasDD, the activity of caspase-8 increased dra-
matically within 30 minutes (Figure 2). Caspase-3 was
also rapidly activated (Figures 2 and 3a). However, the
majority of mitochondrial depolarization occurred rel-
atively slowly (within 3 hours) (Figure 1d). These data
indicate that 12B1-D1 cells are likely type I cells. We
then assessed the MTP disruption after activation of
FasDD in the presence of casp-8 or casp-3 inhibitor. We
found that neither the casp-8 inhibitor nor the casp-3
inhibitor at 100µM blocked the depolarization of MTP
(Figure 7), even though caspase activity was completely
blocked in the presence of the speciﬁc caspase inhibitor
(Figure 5). Concentrations of caspase inhibitors up to
200µM conﬁrmed that they still could not block the de-
polarization of MTP (data not shown).
Treatmentof12B1-D1cellswithcasp-8inhibitor
andCsArevealsanalternativeapoptoticdeath
signalingpathwayoriginatingfromFas
After oligomerization of FasDD, an adaptor pro-
tein FADD/MORT is recruited, which in turn recruits
procaspase-8 resulting in the latter’s activation [4, 5].
Caspase-8 induces cells to undergo apoptosis by either ac-
tivating downstream caspases through proteolytic cleav-
age [12] or triggering Bid cleavage to target mitochon-
dria [23]. Our data documented that the dimerization of
FasDDresultedinthedepolarizationofMTPeventhough
caspase-8 activity was completely blocked (Figure 5), sug-
gesting that there is a pan-caspase inhibitor-sensitive and
casp-8 inhibitor-insensitive protease or proteases, acti-
vated by the dimerization of FasDD. This protease(s)
may directly activate eﬀector caspases or mitochondria,
or both. It has been demonstrated that CsA can block the
depolarization of MTP, which in turn prevents the release
of cytochrome C and even prevents apoptotic cell death2004:1 (2004) A Novel Fas Death Domain Apoptotic Pathway 47
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Figure 7. Loss of MTP of 12B1-D1 cells after AP20187 treatment in the presence of casp-3 or -8 inhibitor. 12B1-D1 cells, with or
without pretreatment of the indicated caspase inhibitors, were treated with 40nM AP20187 for 4 hours, then washed and stained with
DePsipher (Deψ). The cells were analyzed by ﬂow cytometry. DePsipher aggregates in polarized membranes and is apparent in the
red channel (y-axis in units from 100 to 104). Upon depolarization, DePsipher reverts to a monomeric form with ﬂuorescence in the
green channel (x-axis in units from 100 to 104). At equilibrium (normal resting state), DePsipher should ﬂuoresce in both channels
(cells + DePsipher).
[25, 26, 27, 28]. We tested the ability of CsA to protect
12B1-D1 cells from apoptosis induced by AP20187 treat-
ment. Treatment of 12B1-D1 cells with several diﬀerent
concentrations of CsA could not prevent the externaliza-
tion of PS and cell death induced by AP20187 treatment
(Figure 8a). In addition, treatment with CsA did not pre-
vent the depolarization of MTP and DNA fragmentation
(Figures 8b and 8c). Interestingly, when the 12B1-D1 cells
were pretreated with CsA in combination with casp-8 in-
hibitor, followed by exposure to AP20187, the depolar-
ization of MTP was completely blocked (Figure 8b), as
evaluated by DiOC6[3] retention. Such pretreatment also
blocked DNA fragmentation (Figure 8c). These data in-
dicate that it is necessary to block both caspase-8 activity
and mitochondrial damage in order to prevent apoptotic
signaling initiated by FasDD oligomerization in 12B1-D1
cells.
The ﬁnding that CsA in combination with casp-8 in-
hibitor completely blocks 12B1-D1 apoptosis after dimer-
ization of FasDD suggests that the proposed novel pro-
tease(s) targets mitochondria directly. It has been shown
that activated caspase-8 rapidly cleaves the Bcl fam-
ily member Bid [23, 29, 30], resulting in a truncated
form of the molecule (tBid). tBid is highly proapop-
totic and targets mitochondria by inserting into their
membrane, leading to disruption of transmembrane po-
tential and release of cytochrome C [29]. To explore
whether the proposed protease(s) could cleave Bid and
consequently target mitochondria, we examined the Bid
cleavage in 12B1-D1 cells. Consistent with previous re-
ports [23, 31], Bid was cleaved following dimerization of
FasDD (Figure 9). Bid cleavage started within 30 minutes
of AP20187 treatment and a limited amount of Bid re-
mained uncleaved after 2 hours (Figure 9). As expected,
the pan-caspase inhibitor blocked the cleavage of Bid
completely. In the presence of casp-8 inhibitor, Bid cleav-
age was signiﬁcantly inhibited after 2 hours of AP20187
treatment,butnotcompletelyblocked(Figure 9).Thisre-
sult suggests that other protease(s) may play a role in the
cleavage of Bid [23] in the presence of casp-8 inhibitor
especially, since casp-8 inhibitor did not block FasDD-
mediated apoptosis (Figure 4) and caspase-3 activation
(Figure 6). Furthermore, CsA pretreatment exhibited no
inhibitory eﬀects on Bid cleavage (Figure 9). However,
the combination of CsA with casp-8 inhibitor completely
blocked the cleavage of Bid, suggesting that our proposed
novelapoptoticpathwaycanbypassBidandtargetthemi-
tochondria directly (Figure 10).
DISCUSSION
Our ﬁndings indicate that FasDD oligomerization
can trigger a novel caspase-8-independent apoptotic
pathway. This pathway is activated by FasDD, but is
independent of Bid and the proteolytic activity of
caspase-8. It appears to target mitochondria directly by48 Hanping Feng et al 2004:1 (2004)
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Figure 8. Apoptotic death of 12B1-D1 cells after AP20187 treatment in the presence of CsA and/or casp-8 inhibitor. (a) 12B1-D1
cells, with or without pretreatment of diﬀerent concentrations of CsA, were treated with 40nM AP20187 (AP) for the indicated time,
then washed and stained with Annexin V and PI, and analyzed by ﬂow cytometry. x- and y-axes are as in Figure 4a. (b) 12B1-D1 cells,
with or without pretreatment with caspase inhibitors or CsA, were exposed to 40nM AP20187 for 4 hours, then washed, stained with
mitochondrial probe DiOC6[3], and analyzed by ﬂow cytometry. (c) DNA was extracted from 12B1-D1 cells, treated as described
below, for DNA fragmentation assay: M, 100-bp ladder; lane 1, DNA extracted from 12B1-D1 cells, or from 12B1-D1 cells that were
pretreated with control caspase inhibitor Z-FA-FMK (lane 2); lane 3, DNA extracted from 12B1-D1 cells that have been treated with
AP20187 for 6 hours; lane 4, DNA from cells that pretreated with Z-FA-FMK, or pan-caspase inhibitor Z-VAD-FMK (lane 5), or casp-
8 inhibitor Z-IETD-FMK (lane 6), or casp-3 inhibitor Z-DEVD-FMK (lane 7), in each case pretreatment was followed by 6 hours of
AP20187 treatment; lane 8, 12B1-D1 cells were treated with CsA, or CsA followed by AP20187 treatment (lane 9), or CsA together
with casp-8 inhibitor followed by AP20187 treatment (lane 10).
a Z-VAD-FMK-inhibitable mechanism, suggesting the
existence of a novel protease(s) that we are now attempt-
ing to identify.
Theexecutionofmostifnotallapoptosisrequirescas-
pase activation [32]. Caspase-8 is one apical initial cas-
pase and has been thought to be essential in Fas-mediated2004:1 (2004) A Novel Fas Death Domain Apoptotic Pathway 49
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Figure 10. Proposed caspase-8-independent pathway. Our ﬁndings indicate that FasDD oligomerization can trigger a novel caspase-
8-independent apoptotic pathway. This pathway is activated by FasDD, but is independent of Bid and the proteolytic activity of
caspase-8. It appears to target mitochondria directly by a Z-VAD-FMK-inhibitable mechanism.
apoptosis [10, 11]. Ligand binding-induced trimeriza-
tion of death receptors results in recruitment of the
receptor-speciﬁc adapter protein FADD, which then re-
cruits caspase-8. Activated caspase-8 is known to propa-
gate the apoptotic signal either by directly cleaving and
activating downstream caspases (so-called extrinsic path-
way),orbycleavingtheBH3-containingBcl-2-interacting
protein Bid, which leads to the release of cytochrome
C from mitochondria, triggering the intrinsic mitochon-
drial pathway [29]. After triggering the oligomeriza-
tion of FasDD in 12B1-D1 cells by AP20187, caspase-
8 is activated rapidly. Other eﬀector caspases, such as
caspase-3 and -7, are also activated within 30 minutes of
AP20187 exposure, which may result from direct cleav-
age and activation of caspase-3. While activated caspase-
8 can propagate apoptotic signals and initiate the extrin-
sic death receptor pathway, it has also been shown that
the mitochondria-mediated caspase-9 activation path-
way (intrinsic pathway) ampliﬁes Fas signaling through
caspase-8-mediatedcleavageofBidandtranslocationinto
the mitochondria [23, 29]. In our study, we found that
the proapoptotic Bcl-2 family protein Bid was cleaved,
MTP was disrupted, and caspase-9 was activated after the
activation of FasDD. This indicates that the extrinsic and
intrinsic pathways of caspase activation are extensively in-
terconnected in 12B1-D1 cells.
Irreversible oligopeptide caspase inhibitors have been
used extensively to study the role of caspases in apop-
tosis. Z-IETD-FMK and Z-DEVD-FMK block caspase-
8- and caspase-3-like proteases, respectively, whereas Z-
VAD-FMK is a broad-range caspase inhibitor [21, 22].
We observed that neither casp-8 inhibitor nor casp-3 in-
hibitor prevented FasDD-mediated apoptotic cell death
in 12B1-D1, even at concentrations of 200µM, whereas
only 20µM pan-caspase inhibitor completely blocked cell
death. Both casp-3 and casp-8 inhibitors entered the cells
eﬀectively, as pretreatment of the cells with pan-caspase
inhibitor, or either casp-3 or casp-8 inhibitor eﬃciently
blocked cleavage of the ﬂuorogenic substrate DEVD-AFC
or IETD-AFC. A panel of other peptide caspase inhibitors
(for caspase-1, -2, -4, -6, -9, -10, and -13) was also
tested and did not block FasDD-induced apoptosis as
determined by Annexin V-FITC/PI staining. Caspase-10
is a apical caspase [33] and can function independently
of caspase-8 in initiating Fas- and TRAIL (tumor necro-
sis factor-related apoptosis-inducing ligand) -mediated50 Hanping Feng et al 2004:1 (2004)
apoptosis [34]. Consistent with another report [10], we
found that although caspase-10 is expressed in 12B1-D1
cells, it is not proteolytically cleaved and activated, even
after 2 hours of AP20187 exposure, a time point when
caspase-8 activity reached its maximum. In addition, the
caspase-10 inhibitor Z-AEVD-FMK did not block 12B1-
D1 cells from undergoing apoptosis as monitored by An-
nexin V-FITC/PI staining. Furthermore, the casp-8 in-
hibitor also has strong inhibitory activity for caspase-10
[22], since caspase-10 is highly homologous to caspase-
8[ 30, 35]. These ﬁndings indicate that caspase-10 is
not involved in the novel apoptotic pathway that we are
proposing.
Mitochondria play a critical role in mediating apop-
totic signal transduction pathways [36]. Biochemical and
structural changes of mitochondria in apoptosis include
swelling, disruption of the outer membrane, depolariza-
tion, and the release of cytochrome C [36] .C s Ai sc a -
pable of blocking the depolarization of MTP, which in
turn prevents cytochrome C release and even prevents
apoptotic cell death [25, 26, 27, 28]. FasDD dimeriza-
tion by AP20187 resulted in the disruption of mitochon-
drial outer membrane and loss of transmembrane po-
tential as determined by both DiOC6[3] retention and
DePsipher exclusion. This eﬀect could not be blocked
by pretreatment of 12B1-D1 cells with either casp-8 in-
hibitor or CsA. Growing evidence indicates that the ex-
trinsic death receptor and intrinsic mitochondrial apop-
totic pathways are highly interconnected and Bid plays
a major role in this connection [29]. Cytosolic Bid can
be eﬃciently cleaved by activated caspase-8, and tBid
then translocates from cytosol to the mitochondria mem-
brane, resulting in disruption of its outer membrane [23].
We found that Bid was rapidly cleaved after the acti-
vation of FasDD, even when cells were pretreated with
CsA. High levels of tBid may damage the mitochon-
drial outer membrane even if cells are pretreated with
CsA. This may explain our ﬁnding that CsA pretreat-
ment did not block the disruption of MTP. We noticed
that pretreatment of 12B1-D1 cells with casp-8 inhibitor
decreased the cleavage of Bid substantially but not com-
pletely after activation of FasDD. This ﬁnding raises the
question again whether or not the casp-8 inhibitor com-
pletely blocked the proteolytic activity of caspase-8. Pre-
vious reports have shown that certain caspases other
than caspase-8 have minor proteolytic activity towards
Bid [23]. Our data demonstrated that caspases were ac-
tivated and cells underwent apoptotic death after dimer-
ization of FasDD by AP20187 when the cells were pre-
treated with casp-8 inhibitor. Pretreatment of cells with
CsA and casp-8 inhibitor, however, completely blocked
apoptotic cell death, as well as caspase activation and
Bid cleavage, conﬁrming that the proteolytic activity of
caspase-8 was adequately inhibited by the inhibitor since
CsA had no inhibitory eﬀect on Bid cleavage. The fact
that CsA in combination with casp-8 inhibitor com-
pletely blocked 12B1-D1 cells from undergoing apop-
tosis after dimerization of FasDD indicates that the
protease/pathway that we proposed targets the mitochon-
dria directly.
Although knockout data indicate that caspase-8 may
be required for apoptosis induced by the death receptor
Fas [10, 11] in certain cases, other reports have shown
that Fas can induce cell death independent of caspase-8.
Recently, Yang et al showed that Fas can engage an apop-
totic pathway independent of FADD and caspase 8 [13].
They found that Fas activation induced Daxx interaction
with apoptosis signal-regulating kinase 1 (ASK1), lead-
ing to its activation and resulting in caspase-independent
activation of JNK and cell death [14, 15]. This pathway,
however, was not blocked by the broad-spectrum cas-
pase inhibitor, Z-VAD-FMK, distinguishing it from the
pathway we are now proposing. More recently, several re-
ports have shown that Fas signaling can trigger an alter-
native, caspase-8-independent necrotic cell death path-
way. This pathway is not blocked by the broad-spectrum
caspase inhibitor, [16, 17] and that inhibitor even ren-
dered the cells more sensitive to Fas-mediated cell death
[18]. Our data show that the activation of FasDD re-
sulted in the externalization of PS, disruption of MTP,
and DNA fragmentation/laddering when caspase-8 pro-
teolytic activity was completely blocked, suggesting that
cells underwent a cell death with typical apoptotic fea-
tures. In summary, our ﬁndings indicate that FasDD can
trigger a novel caspase-8-independent apoptotic pathway.
This pathway is activated by FasDD, is independent of
Bid and the proteolytic activity of caspase-8, and tar-
gets mitochondria by a Z-VAD-FMK-inhibitable mecha-
nism.
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